Cardiovascular System Screening Package

- ECG
- Treadmill effort test
- EKO
- PLAC test

Inflammation and atherosclerotic plaque formation is the main underlying cause of cardiovascular disease development.

Is it possible to be aware of asymptomatic atherosclerotic plaques?

They can be detected with the aid of PLAC test. The PLAC test makes the intravenous changes responsible for the heart attack visible, measuring the activity of enzymes released from atherosclerotic plaques. The lipoprotein-associated phospholipase A2 (Lp-PLA2) enzyme is produced by atherosclerotic plaques that cause inflammation and narrowing, then released into the bloodstream. The PLAC is a test that measures the activity of this enzyme (Lp-PLA2) released by plaques. The PLAC test is approved by the Food and Drug Administration (FDA). The FDA recommends that the PLAC test will be a screening test to evaluate the risk of developing the future coronary vascular diseases, heart attack, stroke and sudden deaths.